Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Urinary Bladder Neoplasms 33Neoplasm Metastasis 20Lung Neoplasms 20Ovarian Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Neoplasms 14Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Fallopian Tube Neoplasms 10Recurrence 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Melanoma 4Gastrointestinal Neoplasms 4

Interventions

olaparib 1gallium 68 PSMA-11 1Pluvicto 1Gemcitabine 1Cisplatin 1Androgen Antagonists 1Adrenal Cortex Hormones 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × Gemcitabine × 90 days × Clear all
NCT00210041 2026-05-15

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Institut Claudius Regaud

Phase 2 Completed
50 enrolled

Genital Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡